Cargando…
Pegylated liposomal doxorubicin in patients with epithelial ovarian cancer
OBJECTIVE: To evaluate the efficacy and safety of PLD in treating of in patients who experience epithelial ovarian, fallopian tubal, and peritoneal cancer progression within 12 months after the first-line platinum-based therapy. METHODS: This was an open-label, single-arm and multicenter clinical tr...
Autores principales: | Yuan, Zhen, Zhang, Ying, Cao, Dongyan, Shen, Keng, Li, Qingshui, Zhang, Guonan, Wu, Xiaohua, Cui, Manhua, Yue, Ying, Cheng, Wenjun, Wang, Li, Qu, Pengpeng, Tao, Guangshi, Hou, Jianqing, Sun, Lixin, Meng, Yuanguang, Li, Guiling, Li, Changzhong, Shi, Huirong, Chen, Yaqing |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7798203/ https://www.ncbi.nlm.nih.gov/pubmed/33423683 http://dx.doi.org/10.1186/s13048-020-00736-2 |
Ejemplares similares
-
Pegylated liposomal doxorubicin for myeloid neoplasms
por: Zhang, Cheng, et al.
Publicado: (2019) -
Pegylated liposomal doxorubicin in ovarian cancer
por: Green, Andrew E, et al.
Publicado: (2006) -
Pegylated liposomal doxorubicin in ovarian cancer
por: Strother, Robert, et al.
Publicado: (2009) -
Effect of Apatinib Plus Pegylated Liposomal Doxorubicin vs Pegylated Liposomal Doxorubicin Alone on Platinum-Resistant Recurrent Ovarian Cancer: The APPROVE Randomized Clinical Trial
por: Wang, Tiantian, et al.
Publicado: (2022) -
Serious stomatitis and esophagitis: a peculiar mucous reaction induced by
pegylated liposomal doxorubicin
por: Ma, Han, et al.
Publicado: (2015)